Tag: Tivdak
Tisotumab Vedotin Significantly Prolongs Overall Survival in Patients with Recurrent/Metastatic Cervical...
Results today from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin (Tivdak®; Seagen/Genmab)* demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy (HR: 0.70, 95% CI: 0.54-0.89, p=0.0038).[1]
Pfizer to Acquire Seagen for US $ 43 Billion
Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...
Promising Preliminary Data on Tisotumab Vedotin in Patients with Head and...
Preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (Tivdak®; Seagen and Genmab) as a monotherapy in patients...
US FDA Grants Accelerated Approval to Tisotumab Vedotin for Recurrent or Metastatic...
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tisotumab vedotin-tftv (Tivdak™; Seagen/GenMab; previously known as HuMax®-TF-ADC), a first-in-class and only approved...
